Showing results (651-660 of 769) with videos related to

Sort By:
Pageof 77
International Journal of Oncology|October 4, 2006
Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experienceErlinda M Gordon, Francisco F Lopez, Gerardo H Cornelio, et al.
Neurosurgery|September 9, 2015
Haptoglobin 2-2 Genotype Is Associated With Cerebral Salt Wasting Syndrome in Aneurysmal Subarachnoid HemorrhageSantosh B Murthy, Justin Caplan, Andrew P Levy, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 1, 1996
Thoracoscopic laser bullectomy: a prospective study with three-month resultsS Hazelrigg, T Boley, J Henkle, et al.
Journal of the American College of Cardiology|October 14, 2008
Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaquePedro R Moreno, K Raman Purushothaman, Meera Purushothaman, et al.
Journal of Neurosurgery|April 10, 2012
Multimodality management of Spetzler-Martin Grade III arteriovenous malformationsParitosh Pandey, Michael P Marks, Ciara D Harraher, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Proton therapy for prostate cancer: the initial Loma Linda University experienceJerry D Slater, Carl J Rossi, Les T Yonemoto, et al.
Psychiatry Research|April 26, 2006
Comparison between hyperventilation and breath-holding in panic disorder: patients responsive and non-responsive to both testsAntonio E Nardi, Alexandre M Valença, Marco A Mezzasalma, et al.
Diabetes|June 14, 2013
Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications studyTrevor J Orchard, Wanjie Sun, Patricia A Cleary, et al.
Hypertension (Dallas, Tex. : 1979)|November 11, 2025
Haptoglobin Phenotype and Cardiovascular Risk: The ACCORD Blood Pressure RCTSamantha K Lavallée, Allie S Carew, Rachel A Warren, et al.
Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.
Pageof 77